Abiopharma

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

ASE Technology Holding Co., Ltd. Announces Monthly Net Revenues*

FLSmidth: Transactions under share buy-back programme

Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

Innate Pharma - Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

Innate Pharma fait progresser lacutamab vers la phase 3 à la suite de son partenariat avec Sobi et nomme un nouveau directeur médical

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

Private placement of 9,958,297 shares to 2 offerees

Innate Pharma - Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

ASM announces start of €150 million share buyback program